A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium

This study has been completed.
Sponsor:
Information provided by:
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT00125736
First received: July 29, 2005
Last updated: January 28, 2010
Last verified: January 2010
  Purpose

The purpose of this study is to investigate the efficacy and safety of combination use of E0671 and Rabeprazole Sodium in patients with gastric ulcer.


Condition Intervention Phase
Stomach Ulcer
Drug: Teprenone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium

Resource links provided by NLM:


Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • Ratio of S2-stage transition at 8 weeks after the study administration.

Estimated Enrollment: 520
Study Start Date: August 2005
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Detailed Description:

The efficacy and safety of E0671 in combination with Rabeprazole Sodium (i.e., 10 mg/day of rabeprazole sodium and 150 mg/day of E0671) will be investigated in patients with gastric ulcer in a multicenter, randomized, double-blind, parallel-group comparative study using a placebo control group (10 mg/day of rabeprazole sodium and placebo for E0671).

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Patients with gastric ulcer (A1-and A2-stage)
  2. Patients with gastric ulcer who meet all of the following items. Gender and treatment class (in-patient or out-patient) are not asked.

    • Patients with endoscopically diagnosed A1- or A2-stage ulcer (by Sakita/Miwa classification).
    • Patients who are not younger than 20 years of age at the time of obtaining informed consent.
    • Patients who meet any of the following conditions:

      • H. pylori-negative
      • H. pylori-positive and not requiring eradication therapy
      • H. pylori-positive and unsuccessful eradication
  3. Patients who are given a full explanation about the study objective and design, and able to give prior consent for study participation.

Exclusion criteria:

  1. Patients with a complication of duodenal ulcer (excluding cicatrix).
  2. Patients with reflux esophagitis
  3. Patients with acute gastric mucosal lesions (AGML).
  4. Patients with NSAID-induced ulcer.
  5. Patients with linear ulcer.
  6. Patients with ulcer injured by endoscopy.
  7. Patients who underwent gastrectomy or vagal nerve resection.
  8. Patients who are not applied to pharmacotherapy, i.e., perforation, pyloric stenosis, major bleeding (exposed blood vessels in the base of ulcer), etc.
  9. Patients receiving proton pump inhibitor (PPI) and/or teprenone preparation(s) within 1 week prior to the study administration.
  10. Patients with serious cardiovascular diseases (e.g., angina pectoris, heart failure, acute myocardial ischemia, severe tachyarrhythmia), serious hematological disorders (e.g., aplastic anemia), serious renal disorders (e.g., acute, chronic renal failure), serious hepatic disorders (e.g., cirrhosis, severe hepatitis), serious pancreatic disorders (e.g., severe pancreatitis), serious psychoneuroses (e.g., schizophrenia, alcoholic dependency, drug dependency, severe depression), or cancer.
  11. Patients with a current or a history of drug allergy to teprenone preparation(s).
  12. Patients with a current or a history of drug allergy to PPI.
  13. Patients requiring antacid(s) containing digoxin or aluminum hydroxide/magnesium hydroxide that are suspected to exert drug interaction with rabeprazole sodium.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00125736

Locations
Japan
Kariya, Aichi, Japan
Nagoya, Aichi, Japan
Seto, Aichi, Japan
Toyoake, Aichi, Japan
Toyohashi, Aichi, Japan
Akita, Akira, Japan
Urayasu, Chiba, Japan
Niihama, Ehime, Japan
Chikushino, Fukoka, Japan
Kurume, Fukoka, Japan
Oumuta, Fukoka, Japan
Tagawa, Fukoka, Japan
Sabae, Fukui, Japan
Hashima, Gifu, Japan
Asahikawa, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Miki, Hyogo, Japan
Kanazawa, Ishikawa, Japan
Kumamotoi, Kumamoto, Japan
Sendai, Miyagi-prefecture, Japan, 982-8501
Kashihara, Nara, Japan
Yufu, Oita, Japan
Ikeda, Osaka, Japan
Izumisano, Osaka, Japan
Kadoma, Osaka, Japan
Takatsuki, Osaka, Japan
Hasuda, Saitama, Japan
Kitaadachi-gun, Saitama, Japan
Matue, Shimane, Japan
Hamamatsu, Shizouka, Japan
Minato-ku, Tokyo, Japan
Shinagawa-ku, Tokyo, Japan
Shinjyuku-ku, Tokyo, Japan
Shimonoseki, Yamaguchi, Japan
Fukoka, Japan
Gifu, Japan
Hiroshima, Japan
Kouchi, Japan
Kyoto, Japan
Nara, Japan
Nigata, Japan
Oita, Japan
Saga, Japan
Sponsors and Collaborators
Eisai Limited
Investigators
Study Director: Toshihisa Arai GI Group. Post-Marketing Clinical Research Dept., Clinical Research Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00125736     History of Changes
Other Study ID Numbers: E0671-J081-291
Study First Received: July 29, 2005
Last Updated: January 28, 2010
Health Authority: Japan: Ministry of Health, Labor and Welfare

Additional relevant MeSH terms:
Ulcer
Stomach Ulcer
Pathologic Processes
Peptic Ulcer
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases
Rabeprazole
Anti-Ulcer Agents
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 22, 2014